Residual Solvents Analysis Based on the 2025 USP <467> and Chinese Pharmacopoeia (ChP 0861)

Importance of the topic

Residual solvent testing is a mandatory quality control activity in pharmaceutical development and manufacturing because volatile organic compounds introduced during synthesis, purification, or formulation can present toxicological risks to patients. Harmonized pharmacopeial procedures (USP <467> and ChP 0861) set solvent classification, concentration limits, and system suitability criteria that laboratories must meet. Recent 2025 updates expanded the class 2B solvent list and tightened performance expectations, increasing analytical scope and operational demands on routine residual solvent analysis.

Objectives and study overview

This application study demonstrates a headspace GC/FID workflow that complies with the 2025 USP <467> revision and the Chinese Pharmacopoeia General Chapter 0861. Primary aims were to show simultaneous screening and confirmation using a single-inlet, dual-column, dual-FID configuration; to compare helium and nitrogen as carrier gases; and to evaluate system performance, repeatability, and suitability checks supported by the Agilent 8890B GC intelligent diagnostics.

Methodology and instrumentation

• Sampling: Headspace sampling using an Agilent 8697 headspace autosampler with 20 mL vials, vial equilibration (40 min) and controlled shaking.
• Chromatography: Agilent 8890B GC with a single split inlet feeding an unpurged two-way splitter to run columns in parallel: DB-Select 624 UI (30 m × 0.32 mm, 1.8 µm) and DB-WAX UI (30 m × 0.32 mm, 0.25 µm), each connected to its own FID detector.
• Carrier gas and flow: Both helium and nitrogen were evaluated at constant flow (≈2 mL/min) with slight oven program adjustments between gases.
• Detection and acquisition: Dual FID channels, 10 Hz data rate; signal-to-noise (PtoP) used for sensitivity evaluation. Data acquired with Agilent OpenLab CDS v2.8.
• Standards: USP-specified class 1, 2A, and 2B residual solvent standard mixtures prepared at pharmacopoeial limit concentrations; individual standards (e.g., MIBK, cumene) used for select checks.

Instrumentation used

• Agilent 8697 Headspace Sampler
• Agilent 8890B Gas Chromatograph with GC Assist (intelligent performance checks and guided troubleshooting)
• Columns: Agilent DB-Select 624 UI and Agilent DB-WAX UI
• Detectors: Dual flame ionization detectors (dual-FID configuration)

Main results and discussion

• Chromatographic performance: Dual-column/dual-FID setup enabled simultaneous screening and orthogonal confirmation. Most target solvents achieved baseline separation on at least one column; pairs that coeluted on one phase were often resolved on the orthogonal phase.
• Sensitivity and signal-to-noise: Representative S/N values met USP <467> limits. For procedure A with helium, 1,1,1-trichloroethane S/N = 78.3, carbon tetrachloride S/N = 11.1; with nitrogen S/N = 67.8 and 9.6 respectively. Benzene S/N in procedure B reached ~105 with both gases. Some low-response analytes (e.g., 1,4-dioxane, 1,2-dimethoxyethane, nitromethane) required attention to integration settings.
• Resolution: Critical pharmacopeial resolution requirements were met. Example: acetonitrile/methylene chloride resolution = 3.4 (He and N2); acetonitrile/MIBK resolution = 1.9 (He) and 1.4 (N2) — both meeting USP acceptance for the evaluated conditions. The newly added class 2B pair (1,2-dimethoxyethane vs cyclopentyl methyl ether) showed resolutions of 3.7 (He) and 3.4 (N2), exceeding the ≥1.5 requirement.
• Repeatability: Peak area repeatability across nine consecutive injections was excellent. Average area %RSD was 1.32% (He) and 1.28% (N2), with roughly half of analytes showing area RSDs <1%. Retention time stability was strong: average RT %RSD ≈0.009% on DB-Select 624 UI and ≈0.018% on DB-WAX UI. The WAX phase exhibited slightly higher RT variability due to sensitivity to water vapor introduced from headspace vials.
• Single-run mixed analysis: A combined 32-compound standard (classes 1, 2A, 2B) was analyzed in one injection. Most compounds were baseline separated overall; the dual-column approach resolved many coelutions that would confound single-column assays. Remaining coelutions may be addressed by mass spectrometric detection if needed.
• Pharmacopeial alignment: The method satisfies USP <467> mandatory system suitability metrics (S/N thresholds and resolution) and aligns with ChP 0861 principles; ChP allows more flexible, risk-based suitability criteria tailored by laboratories.

Benefits and practical applications

• Time efficiency: Dual-column, dual-FID single-injection workflow combines screening and confirmatory separations, reducing total run time vs sequential analyses.
• Operational flexibility: Validated performance with both helium and nitrogen supports laboratories facing helium supply or cost constraints while maintaining data quality.
• User support and reliability: Agilent 8890B GC Assist provides built-in peak evaluation, pass/fail reporting, and stepwise guided troubleshooting (method checks, leak testing, guided column exchange), lowering downtime and easing use for less experienced operators.
• Regulatory compliance: Workflow meets USP <467> and ChP 0861 requirements for residual solvent testing, supporting routine QC in biopharma and pharma environments.

Future trends and potential uses

• Carrier gas flexibility will remain important as helium availability and cost continue to affect laboratory operations; validated nitrogen workflows will be increasingly adopted.
• Integration of orthogonal detectors (e.g., MS) alongside dual-column FID setups can further strengthen qualitative confirmation for coeluting or low-response analytes.
• Automated, software-guided system suitability and troubleshooting will expand, supporting 21 CFR Part 11‑compliant reporting, remote diagnostics, and reduced operator dependency.
• Method miniaturization and faster headspace equilibration strategies may be explored to increase throughput while preserving chromatographic resolution required by updated regulatory lists.

Conclusion

A headspace GC/FID method using an Agilent 8697 headspace sampler coupled to an Agilent 8890B GC with dual DB‑Select 624 UI and DB‑WAX UI columns delivers robust, pharmacopeia-compliant residual solvent testing under USP <467> (2025) and ChP 0861. The dual-column, dual-FID single-injection approach provides efficient screening plus orthogonal confirmation. Analytical performance—sensitivity, resolution, and repeatability—was excellent for both helium and nitrogen carriers. Built-in GC Assist features further improve routine operation and troubleshooting, making the workflow practical for regulated pharmaceutical QC laboratories.

Reference

1. United States Pharmacopeia and National Formulary. USP-NF <467> Residual Solvents. 2025 edition.
2. Chinese Pharmacopoeia. General Chapter 0861: Residual Solvents. 2025 edition.
3. International Council for Harmonisation (ICH). Q3C: Impurities—Residual Solvents.